STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's...
Read More Details
Finally We wish PressBee provided you with enough information of ( Therapeutic Goods Administration decides not to register lecanemab in Australia )
Also on site :
- Iconic '80s Sitcom Bombshell, 66, Unrecognizable In Very Rare Sighting
- Syria’s National Authority for Transitional Justice defines its plan
- Aldi Is Selling Comfy $7 Lightweight Sandals That Look Just Like Birkenstocks 7x the Price